STOCK TITAN

Farallon group discloses 16.27M Tango Therapeutics (TNGX) shares and warrants

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Farallon Capital Management, L.L.C. and affiliated funds report beneficial ownership of Tango Therapeutics, Inc. common stock. The Farallon Funds together hold 12,277,000 Shares and 3,993,187 Pre-Funded Common Stock Purchase Warrants, each warrant exercisable for one Share, subject to a 9.99% Beneficial Ownership Limitation. Assuming all warrants are exercisable within 60 days, the Reporting Persons disclose beneficial ownership of 16,270,187 Shares, representing 9.8% of Tango’s outstanding common stock. Farallon Capital Management acts as investment manager to the Farallon Funds, and multiple individual managing members share voting and dispositive power over these securities.

Positive

  • None.

Negative

  • None.
Directly held Shares 12,277,000 Shares Common stock of Tango Therapeutics held by the Farallon Funds
Pre-Funded Warrants 3,993,187 Warrants Pre-Funded Common Stock Purchase Warrants, each exercisable for one Share
Total beneficial ownership 16,270,187 Shares Aggregate Shares beneficially owned assuming all warrants exercisable within 60 days
Ownership percentage 9.8% Percentage of Tango Therapeutics common stock beneficially owned by Reporting Persons
Beneficial Ownership Limitation 9.99% Cap on ownership after warrant exercise under the warrant terms
Par value per share $0.001 per share Par value of Tango Therapeutics common stock
Beneficial Ownership Limitation regulatory
"may not be exercised to the extent that... more than 9.99% of the Shares then issued"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
Pre-Funded Common Stock Purchase Warrants financial
"3,993,187 Pre-Funded Common Stock Purchase Warrants (the "Warrants")"
A pre-funded common stock purchase warrant is a contract that gives an investor the right to receive a company’s common shares later after having paid nearly the full share price up front, leaving only a very small remaining payment to convert the warrant into an actual share. Think of it like reserving a product by paying almost everything now and paying a tiny balance later; it provides immediate capital to the company, limits immediate dilution of outstanding shares, and lets investors manage ownership limits and timing of when they actually hold tradable stock.
beneficially owned regulatory
"the securities reported hereby as beneficially owned by the Reporting Persons"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
investment manager financial
"Farallon Capital Management, L.L.C., a Delaware limited liability company (the "Investment Manager")"
Schedule 13G regulatory
"Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

What percentage of Tango Therapeutics (TNGX) does Farallon report owning?

Farallon and its related funds report beneficial ownership of 9.8% of Tango Therapeutics’ outstanding common stock, based on 16,270,187 Shares deemed beneficially owned, including shares underlying pre-funded warrants assumed exercisable within 60 days.

How many Tango Therapeutics (TNGX) shares do the Farallon funds hold directly?

The Farallon Funds directly hold 12,277,000 Shares of Tango Therapeutics common stock. In addition, they hold 3,993,187 pre-funded common stock purchase warrants, each initially exercisable for one additional Share, subject to a 9.99% Beneficial Ownership Limitation.

What is the Beneficial Ownership Limitation mentioned for Tango Therapeutics (TNGX)?

The warrants include a 9.99% Beneficial Ownership Limitation, preventing exercise if it would cause Farallon to beneficially own over 9.99% of Tango’s outstanding Shares. As of the reporting date, this limitation does not restrict exercising any of Farallon’s warrants.

Who are the reporting persons in the Tango Therapeutics (TNGX) Schedule 13G/A filing?

Reporting Persons include Farallon Capital Management, L.L.C. as investment manager to the Farallon Funds and several managing or senior managing members, collectively the Farallon Individual Reporting Persons, who share voting and dispositive power over the reported Tango securities.

Which Farallon entities directly hold Tango Therapeutics (TNGX) securities?

The securities are held by multiple Farallon investment partnerships, collectively the Farallon Funds, including FCP, FCIP, FCIP II, FCIP III, FCIP V, FCOI II, FCAMI, F5MI, and FHPM, for which Farallon Capital Management, L.L.C. serves as investment manager.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





87583X109

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Farallon Capital Management, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member
Date:08/14/2026
Farallon Capital Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/14/2026
Farallon Capital Institutional Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/14/2026
Farallon Capital Institutional Partners II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/14/2026
Farallon Capital Institutional Partners III, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/14/2026
Four Crossings Institutional Partners V, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager of its General Partner
Date:08/14/2026
Farallon Capital Offshore Investors II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/14/2026
Farallon Capital (AM) Investors, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/14/2026
Farallon Capital F5 Master I, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager of its General Partner
Date:08/14/2026
Farallon Healthcare Partners Master, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager of its General Partner
Date:08/14/2026
Farallon Partners, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member
Date:08/14/2026
Farallon Institutional (GP) V, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager
Date:08/14/2026
Farallon F5 (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager
Date:08/14/2026
Farallon Healthcare Partners (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager
Date:08/14/2026
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:08/14/2026
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Husen, Avner A.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026

Comments accompanying signature: Each of Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C, and Farallon Healthcare Partners (GP), L.L.C. has executed this statement in Mill Valley, California, on behalf of itself and each fund for which it is the general partner.
Exhibit Information

Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)